HMGB1 and neoplasm: By inducing CRT exposure and HMGB-1 release, OxPt/DHA directly converted treated tumours into an in situ vaccine, recruiting antigen-presenting DCs and macrophages, facilitating cancer cell phagocytosis, enhancing antigen processing and presentation, and finally increasing intratumoural infiltration of CD8+ T cells to significantly potentiate checkpoint blockade immunotherapy.